---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-094875"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2024-04-12T23:59:59+00:00"
generated_at: "2026-06-03T23:22:55.476692+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nurix prices upsized $175M public offering of 10.17M shares and prefunded warrants at $15.00/share

## Summary
- 10,166,667 common shares at $15.00/share plus 1,500,100 pre-funded warrants at $14.999/warrant.
- Gross proceeds of $175M; net proceeds estimated at ~$164M after underwriting discounts and expenses.
- Proceeds to fund clinical development, R&D pipeline expansion, and working capital.
- Underwriters granted 30-day option to purchase up to an additional 1.75M shares.
- Offering expected to close on or about April 16, 2024, subject to customary conditions.

## SEC filing metadata
- accession: 0001193125-24-094875
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2024-04-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000119312524094875/0001193125-24-094875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000119312524094875/d818273d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-094875
- JSON: https://secwatch.observer/filing/0001193125-24-094875.json
- Plain text: https://secwatch.observer/filing/0001193125-24-094875.txt

## Key facts
- Material Agreements
  Nurix Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated valued at Issuance and sale of 10,166,667 shares of common stock at $15.00 per share and pre-funded warrants t (effective 2024-04-11).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated
  - Value: Issuance and sale of 10,166,667 shares of common stock at $15.00 per share and pre-funded warrants t
  - Effective: 2024-04-11
  source text: On April 11, 2024, Nurix Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated, as the representatives of the several underwriters named in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 10,166,667 shares of its common stock (the “Shares”) and (b) pre-funded warrants to purchase 1,500,100 shares of its common stock (the “Pre-Funded Warrants”) to the Underwriters (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000119312524094875/0001193125-24-094875-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.